CMSC: Age, Time to Diagnosis Predict PML Survival - MedPage Today

MedPage Today

CMSC: Age, Time to Diagnosis Predict PML Survival MedPage Today ... associated with greater likelihood of survival in cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab (Tysabri). PML is a rare but extremely serious side effect of natalizumab treatment. ...

Market share of 20% targeted as sales of MS drug Tysabri continue to grow - Irish Times

Irish Times

Market share of 20% targeted as sales of MS drug Tysabri continue to grow Irish Times To date, some 124 Tysabri patients have been diagnosed with the rare brain condition, a potential side effect of the drug, while there have been 23 deaths. Addressing Elan's directors, Mr Walsh invited Elan to make all resources available to ensure his ... and more »

Pills Offer Easier Way to Treat MS - Wall Street Journal

Pills Offer Easier Way to Treat MS Wall Street Journal Still, he says, many physicians are being cautious about prescribing the oral drugs because their side effects can't be fully assessed until they are used widely for an extended period of time. Among its side effects, Gilenya can increase a person's ... and more »

Deals Of The Week: Outsourcing - The IN VIVO Blog (blog)

The IN VIVO Blog (blog)

Deals Of The Week: Outsourcing The IN VIVO Blog (blog) ... which has serious bleeding side effects and questionable efficacy in the broad sepsis patient population.--Jessica Merrill Medco/Exagen: Can Medco do for methotrexate in rheumatoid arthritis what it's done for warfarin in the blood thinner market? ... and more »